In This Article:
-
Sales Revenue: Slight decline of 1.3% in constant currencies for the first 9 months of 2024, totaling EUR 2,029 million.
-
Order Intake: Increased by 8.5% in constant currencies, reaching EUR 2.326 billion.
-
EBITDA Margin: 27.8% for Sartorius Stedim Biotech, with a group-level margin of 27.7% for the first 9 months.
-
Net Operating Cash Flow: Increased to EUR 530 million from EUR 410 million in the prior year period.
-
CapEx Ratio: Reduced to 12.8% for Sartorius Stedim Biotech, with a group-level target of around 12% for the full year.
-
Net Debt: Decreased to EUR 2,349 million for Sartorius Stedim Biotech, with a group-level net debt of EUR 3.946 billion.
-
Net Debt-to-EBITDA Ratio: 3.1 for Sartorius Stedim Biotech, with a group-level ratio of 4.4 times.
-
Regional Performance: EMEA sales grew by almost 6%, Asia Pacific sales increased by 1.3%, while Americas sales declined by almost 10%.
Release Date: October 17, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Sartorius Stedim Biotech SA (SDMHF) confirmed its guidance for the full year 2024, indicating confidence in meeting its financial targets.
-
The company reported a significant increase in order intake, particularly driven by consumables, reflecting a positive trend in recurring business.
-
Efficiency programs are positively impacting profitability, with expectations of further contributions in Q4.
-
The EMEA region showed strong performance with approximately 5% growth, indicating regional strength.
-
Cash flow significantly increased due to effective working capital and CapEx management, showcasing financial discipline.
Negative Points
-
Sales revenue for the first 9 months of 2024 was slightly negative compared to the prior year, indicating challenges in achieving growth.
-
The equipment business remains soft, with ongoing reluctance from customers to invest, particularly impacting the Bioprocess Solutions division.
-
The Asia region, especially China, continues to underperform due to market corrections and local competition.
-
Underlying EBITDA margin saw a slight decline due to mix effects and lower production volumes.
-
The company faces challenges in the U.S. market due to overcapacity and destocking effects from the pandemic.
Q & A Highlights
Q: How did the mix in Bioprocess Solutions (BPS) orders develop in Q3 between consumables and equipment? A: Joachim Kreuzburg, Sartorius AG and Sartorius Stedim Biotech SA - IR, explained that there was a healthy recovery in demand for consumables, reflecting progress in customer stock level reductions. However, there remains a reluctance among customers to invest in equipment, leading to a mix trend towards consumables in the order intake.